Maurizio Zangari
Professor
Also affiliated: University of Maryland, Baltimore (2003); Grant Medical Center (2002); Mount Sinai Hospital (1999); Hackensack University Medical Center (2003); NewYork–Presbyterian Hospital (2009); Medical College of Wisconsin (2003); Cornell University (2009); University of Utah (2008–2019); University of Arkansas Medical Center (2016–2019); Huntsman Cancer Institute (2009–2019); Saint Vincent Health System (2003); Fred Hutch Cancer Center (2000); Central Arkansas Veterans Healthcare System (2001–2002); Cancer Research And Biostatistics (2003–2008); Dana-Farber Cancer Institute (2003); Myeloma UK (2009–2018); Cancer Research Center (2001); Winthrop Rockefeller Foundation (2020–2025); SWOG Cancer Research Network (2000); Bristol-Myers Squibb (Switzerland) (2001); Icahn School of Medicine at Mount Sinai (1995–1999)
Faculty Researcher
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Maurizio Zangari, M.D. is a Professor of Medicine at the University of Arkansas for Medical Sciences (UAMS) Myeloma Institute for Research and Therapy. His research focuses on multiple myeloma, investigating its molecular underpinnings, evolutionary pathways, and the impact of therapeutic interventions. Dr. Zangari has published extensively on topics including the molecular characteristics of smoldering myeloma, the spatio-temporal evolution of the disease, and the role of the immune microenvironment in its progression.
His work also addresses critical aspects of treatment, such as the risk of infections associated with novel therapies like bispecific antibodies, and the changing spectrum of infections in patients undergoing treatment with BCMA and GPRC5D targeting bispecific antibodies. Dr. Zangari has also examined disparities in access to advanced therapies, including CAR T-cells and bispecific antibodies, for multiple myeloma, and contributed to research on the enrollment of Black participants in pivotal clinical trials for hematological malignancies. He holds a highly cited researcher designation, with a significant publication and citation record.
Dr. Zangari's academic background includes fellowship training in Bone Marrow Transplant and Hematology at Mount Sinai Hospital and residency in Internal Medicine at Wykoff Heights Medical Center, both in New York. He earned his M.D. from the University of Padua, Italy. He is board certified in Hematology and Internal Medicine and is a member of the American Society of Hematology. He leads a research group and collaborates with several colleagues at UAMS.
Research Overview
Maurizio Zangari, M.D. is a Professor of Medicine with the Myeloma Institute for Research and Therapy at UAMS. Dr. Zangari trained as a fellow in Bone Marrow Transplant and Hematology at Mount Sinai Hospital in New York and a resident in Internal Medicine at Wykoff Heights Medical Center, also in New York. He earned is MD from the University of Padua in Italy. Dr. Zangari was previously at the Myeloma Center from 1998-2007, then left for the University of Utah from 2007-2013. He rejoined the Myeloma Center in 2013 and continues to be greatly involved with clinical trials and research. He is an internationally recognized expert in multiple myeloma with an extensive bibliography of peer-reviewed articles and invited presentations. Dr. Zangari is board certified in Hematology and Internal Medicine. He is a member of the American Society of Hematology.
Metrics
- h-index: 71
- Publications: 514
- Citations: 19,564
Selected Publications
-
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> . (2026)
-
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
-
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)
-
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)
-
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab (2024)
Research Interests
Hypercoagulability in Cancer Patients. The role of activated protein C in thrombotic manifestation of patients with multiple myeloma. Since the start at the University of Utah I have initiated retrospective and prospective studies of the protein C system function in patients with paraproteinemias and myeloproliferative disorder. I have also continued to test the effect of proteosome inhibition on platelet function. After establishing 5GTM1 C57BL/KaLwRij sub-strain in a pre-clinical model I have tested the function of a proteasome inhibitor through the PTH-PTHR axis. In the last 22 months I focused the research to confirm the hypothesis of the PTH essential role in anti-myeloma proteasome activity testing the effect of PTHR antibodies and the effects of parathyroidectomy. The C57 BLACK MOUSE MODEL will be measured in the presence of different proteasome inhibitors MLN 9708, carfilzomib and CEP 18770. I am the principal investigator in three open investigator-initiated trials (Phase I Exploratory Study of Panobinostat IV in Combination with Relapsed/Refractory Multiple Myeloma Patients; Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients; Bone Effect of Bortezomib in Patients with relapsed/refractory Multiple Myeloma), which focus on the bone anabolic activity of proteasome inhibition to determine the minimal proteosome inhibition associated with the anabolic bone effect in multiple myeloma and to evaluate the effect of proteasome inhibition in smoldering myeloma patients. A phase I study, a combination of two bone anabolic drugs panabinostat (a histone deacetylase inhibitor HDAC) and bortezomib in relapse/refractory multiple myeloma patients.
Grants & Funding
As listed on this researcher's institutional profile.
- 2005-02 (The CAFÉ Study): CAncer-related Fracture Evaluation - A Multicenter, Prospective, Randomized, Controlled Study to Compare Balloon Kyphoplasty Kyphon, Inc Principal Investigator
- UARK 2002-09 Protocol F7SCT-1485, A Multicenter, Randomized, Double Blind, Parallel Groups, Placebo Controlled Trial on Efficacy and Safety of Activat Novo Nordisk Principal Investigator
- MLN 9708 Millennium Pharmaceuticals, Inc. Principal Investigator
- UARK 2002-37, An Open Label Phase II Extension Study to Assess the Long-Term Safety and Tolerability of MRA Given to Patients with Multiple Myeloma Chugai Biopharmaceuticals, Inc. Principal Investigator
Collaboration Network
Top Collaborators
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 54 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 49 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 48 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
Showing 5 of 36 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Showing 5 of 18 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 17 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 14 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Showing 5 of 14 shared publications
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 14 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Showing 5 of 13 shared publications
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
Showing 5 of 13 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 12 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 11 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
Showing 5 of 10 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
Showing 5 of 10 shared publications
Similar Researchers
Based on overlapping research topics